Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

HLA class II plays a crucial role in tumor immune microenvironment and recurrence prediction. This work demonstrates the prognostic and clinical values of HLA class II in patients with SCLC.